Purpose:To compare the efficacy of topical Bromfenac 0.09% combined with topical Prednisone acetate 1% versus topical Prednisilone alone in the management of pseudophakic cystoid macular oedema. Methods:Randomized simple comparative study included 20 eyes of 20 patients diagnosed with cystoid macular oedema (CMO) following uncomplicated phacoemulsification . Ten eyes were received topical Bromfenac 0.09% combined with topical Prednisone acetate 1% while the other 10 eyes received only topical Prednisone acetate 1% . Outcomes were measured at the baseline, one month, two months and three months after treatment by visual acuity assessment, slit lamp biomicroscopic examination and OCT macular thickness scan. Results:Mean baseline BCVA in Group 1 was 0.65±0.23, and after 3 months was 0.35±0.21. Group 2 showed baseline mean visual acuity 0.75 ± 0.19 , at the end of study mean values were 0.35 ±0.21 . Mean macular thickness of Group 1 at baseline were 381.3±72.3µ , while the mean macular thickness of group 2 were 382 ± 115.7 µ . At the end of study macular thickness group 1 mean values were 307.2 ±67.5µ , while group 2 mean values were 356.1 ± 108.82µ .There was statistically significant difference in central macular thickness and visual acuity between baseline values and at two and three months visits . Conclusion:Bromfenac 0.09% combined with topical Prednisone acetate 1% significantly decreased macular thickness and improved visual acuity in cases with postoperative pseudophakic macular oedema compared to patients received topical Prednisone acetate 1% only.